



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicants: J.C. Hunt, et al.

Serial No.: 19/086,409

Filed: November 19, 2001

For: MOUSE MONOCLONAL ANTIBODY

(5-21-3) TO HUMAN

IMMUNODEFICIENCY VIRUS GP41

PROTEIN

Attorney Docket No.: 4573.US.C6

Examiner: Not Yet Assigned

Group Art Unit: 1642

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to as follows:

U.S. Patent and Trademark Office

Box Sequence P.O. Box 2327

Arlington, VA 22202

esit: 0 19-302

Kimberly A. Jorio

STATEMENT TO SUPPORT FILINGS AND SUBMISSIONS IN ACCORDANCE WITH 37 C.F.R. §§1.821 THROUGH 1.825

U.S. Patent and Trademark Office Box Sequence P.O. Box 2327 Arlington, VA 22202

Dear Sir:

The undersigned, being the attorney of record of the above-identified patent application, submits the following statement regarding the Substitute Sequence Listing in paper and computer readable form submitted herewith:

I hereby state that the content of the enclosed substitute paper and computer readable forms of the Sequence Listing are identical, and that they contain no sequence information that would constitute new matter beyond the originally filed application.

Further, it is respectfully requested that the paper copy and computer readable form of the Sequence Listing filed herewith be substituted for those filed on July 25, 2002.

23492

ABBOTT LABORATORIES Telephone: (847) 938-3137

Facsimile: (847) 938-2623

Respectfully submitted,

J.C. Hunt et al.

Dianne Casuto

Registration No. 40,943 Attorney for Applicants